Please Wait...

Gregory Klein

Translation skills

Main profile

Gregory Klein, PhD
Director of Medical Imaging

Gregory Klein brings to BioClinica a multi-faceted medical imaging background, with over 20 years of experience in positron emission tomography (PET) instrumentation, reconstruction and quantification techniques. In his current position, Gregory Klein serves as an in-house PET Imaging expert to advise on acquisition and analysis methods for clinical studies using PET, and to explore new methodologies to more fully exploit the potential of molecular imaging for clinical research.

At the Lawrence Berkeley National Laboratory (LBNL) and the Johns Hopkins University, Dr. Klein developed image reconstruction and quantification methodologies for advanced nuclear medicine functional imaging techniques as well as for structural imaging modalities such as MRI and CT with applications to neuroscience, cardiology and oncology. Following his work at LBNL, Dr. Klein served as Director of Cardiovascular Research at QuantifiCare, S.A., a core lab managing image-based endpoints for drug and device clinical trials, and then opened the first U.S. office for QuantifiCare, serving as its President and CEO. Most recently, Dr. Klein served as a Senior Researcher at the University of Washington School of Public Health, where his work focused on comparative effectiveness research and cost effectiveness of PET and MRI diagnostic methods for staging of breast and lung cancer.

Dr. Klein received his Ph.D. in Vision Science from the University of California at Berkeley, his M.S. in Electrical Engineering from the University of Maryland, and his B.S.E.E. from the University of Nebraska. In addition to his experience with traditional 3D medical imaging modalities, Dr. Klein's expertise has included clinical studies using ophthalmologic optical coherence tomography and fundus photography, as well as dermatologic and cosmetic clinical photography.

Authored Publications

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2014 Nov 24. P1-19.


Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain…
bioclinica (12 hours ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai…
bioclinica (2 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (5 days ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining…
bioclinica (5 days ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch…
bioclinica (2 weeks ago)
RT @MySCRS: @AcurianCaresT2D, @bioclinica, @Medidata, @GreenphireINC, @PAREXEL: these are just some of this year's Global Summit exhibitors…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen